Epidemiology of Psoriasis Market Forecast to 2024 in New Report

PUNE, India, November 24, 2015 /PRNewswire/ --

New market research titled "EpiCast Report: Psoriasis - Epidemiology Forecast to 2024" provides in-depth, high quality, transparent and market-driven expert analysis of disease trends in the 8 Major Markets of the world.

Complete report on Psoriasis - Epidemiology Forecast to 2024 spread across 39 pages with 7 tables and 5 figures is now available at http://www.reportsnreports.com/reports/442033-epicast-report-psoriasis-epidemiology-forecast-to-2024.html .

Psoriasis is a chronic, immune-mediated inflammatory skin disease. Psoriasis ranges in severity from a few scattered, sharply demarcated, scaly, red, coin-sized skin lesions or scaly plaques to involvement of almost the entire body surface. Psoriasis is more prevalent in colder areas, and less prevalent in the tropics and warmer regions of the world. Globally, the one-year prevalence of psoriasis varies with the differences in prevalence of psoriasis attributed to variations in environmental factors, genetic factors, and differences in the case definition used to diagnose psoriasis in epidemiology studies.

Epidemiologists forecast an increase in the one-year diagnosed prevalent cases of psoriasis in the 8MM, from 43,747,201 cases in 2014 to 50,455,013 cases in 2024, with an Annual Growth Rate (AGR) of 1.53% during the forecast period. In 2024, India will have the highest number of one-year diagnosed prevalent cases of psoriasis in the 8MM, with 32,853,676 cases, whereas Japan will have the lowest number of one-year diagnosed prevalent cases of psoriasis, with 482,431 cases in 2024.

Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=442033 .

The report provides an overview of the risk factors, comorbidities, and the global and historical trends for psoriasis in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and India). The report also provides a 10-year epidemiological forecast of the one-year diagnosed prevalent cases of psoriasis segmented by sex, age (at 10-year intervals, starting at age zero years and ending at ages =80 years), and severity (mild, moderate, and severe) in the 8MM. Epidemiologists forecast the one-year diagnosed prevalent cases of psoriasis in the 8MM from 2014-2024 using data obtained from peer-reviewed journals that provide one-year diagnosed prevalence of psoriasis in the respective markets. Psoriasis one-year diagnosed prevalent cases are further segmented by severity.

Another newly published market research titled Scar - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Scar, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scar Pipeline Review research report of 112 pages is available at http://www.reportsnreports.com/reports/431361-scar-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]